Scientific Session Explores Future Role of AI and ML in Clinical Laboratory
|
By LabMedica International staff writers Posted on 26 Jul 2023 |

The enthusiasm surrounding the application of artificial intelligence (AI) and machine learning (ML) in laboratory medicine is unprecedented. This makes it crucial for laboratory professionals to acquire fundamental knowledge of these systems as they are set to become an integral part of clinical practice. At the AACC 2023 scientific session, “Artificial Intelligence and Machine Learning in the Clinical Laboratories: Fundamental Concepts, Clinical Use Cases, and Future Considerations,” attendees learned about the role that AI and ML can play in the clinical laboratory.
Considering the enormous amount of data produced by laboratories, the potential for implementing AI algorithms across all stages of the testing procedure is immense. Nonetheless, to truly harness the power of these algorithms, it's essential to understand and appreciate the functioning of such models. In the first part of the session, Christopher Williams, MD, from the University of Oklahoma Health Sciences Center (Oklahoma City, OK, USA) taught attendees some of the foundational concepts of AI and ML. Williams introduced various types of ML, a subset of AI that includes supervised and unsupervised learning. Williams laid out an understanding of the core concepts that can empower laboratorians to begin questioning why a model makes certain decisions—a skill that can prove useful for those evaluating their own models as well as for those approached by vendors with AI-enabled products.
In the second part of the session, David McClintock, MD, from Mayo Clinic (Rochester, MN, USA) discussed the tools and skills required by laboratory professionals to integrate AI/ML applications in clinical laboratories. This does not mean that laboratorians will have to become coding experts. According to McClintock, there are simple “low-code and no-code” test systems that can aid non-experts in generating AI/ML models. However, he cautioned that it is still vital to think about datasets critically from the laboratory perspective.
“This is where it is more important not to understand the coding but to understand what the model is looking for,” said McClintock. A laboratorian should be able to answer basic questions when developing and using a model such as: “What am I looking for? How do I structure my data? What are the inputs? What are the outputs?”
McClintock also described some of the obstacles hampering the wider distribution of AI/ML. “We don’t expect one group to figure all this out,” he said. Collaboration is key, and McClintock believes it is important for more people with backgrounds in data science to be brought into the laboratory in order to ensure the right support is in place from both the lab side as well as the IT side.
AI holds the power to transform laboratory medicine, although several questions remain unanswered. “There is a time and place for AI, and we’re going to learn what that is,” said McClintock. Laboratorians must be ready and begin understanding where and how AI/ML can fit in. But McClintock made it clear that “AI and ML are coming to your laboratory.”
Thomas Durant, MD, from Yale School of Medicine (Wallingford, CT, USA) discussed various key issues related to the implementation of AI/ML applications, including ethics, interoperability, and regulatory considerations. Patient safety is a key concern for Durant who emphasized that lab professionals must perform their due diligence before integrating AI tools as there can be biases within a model that could cause potential harm.
“We need to collectively as a field develop some degree of technology literacy around these new applications,” said Durant. From there, an acceptable framework can be developed for validating and verifying the performance of these tools.
Related Links:
University of Oklahoma Health Sciences Center
Mayo Clinic
Yale School of Medicine
Latest AACC 2023 News
- First-of-Its-Kind Single-Cell Clinical Microbiology Platform Wins 2023 Disruptive Technology Award
- Ground-Breaking Phage-Based Diagnostic Kit for Laboratory Tuberculosis Testing Presented at AACC 2023
- Laboratory Experts Show How They Are Leading the Way on Global Trends
- Unique Competition Focuses on Using Data Science to Forecast Preanalytical Errors
- Best Approach to Infectious Disease Serology Testing for Laboratorians and Clinicians Discussed at AACC 2023
- Breaking Research Throws Light on COVID, Flu, and RSV Co-Infections
- New Research Shows Self-Collected Tests Perform Similarly to Provider-Collected Tests for Detecting STIs
- AI Predicts Multiple Sclerosis Risk, Flags Potentially Contaminated Lab Results
- Scientific Session Explores Role of Technology in New Era of Specimen Transport
- Prevencio Presents AI-Driven Platform for Medical Diagnostic Test Development
- SARSTEDT Demonstrates Pre-Analytic Innovations for Improving Specimen Quality, Reducing TAT and Automating Labs
- World's First Large Sample Volume, Open-Assay, Super-fast, Ultra-Sensitive, and Sample-To-Answer PCR Instrument
- Vital Biosciences Unveils Revolutionary POC Lab Testing Platform
- World's Smallest POC Device for Complete Blood Count in 30 Minutes Unveiled
- General Biologicals Unveils CTC Cancer Detection Products and Automated Molecular System
- Fapon Showcases Innovative Diagnostic and Biopharma Solutions
Channels
Clinical Chemistry
view channel
Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury
Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more
Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease
Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read moreMolecular Diagnostics
view channel
Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation
Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth
Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read moreMicrobiology
view channel
Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read more
Plasma Cell-Free DNA Test Enables Earlier Diagnosis of Invasive Fungal Infections
Invasive fungal infections disproportionately affect immunocompromised patients, while diagnostic delays can contribute to substantial morbidity and mortality. Existing methods often depend on invasive... Read morePathology
view channel
AI Uses H&E Slides to Predict Key Biomarkers Across 32 Cancers
Molecular profiling is essential for characterizing solid tumors, but many laboratories still rely on separate genetic assays to detect alterations such as TP53 mutations. These workflows can be resource-intensive... Read more
AI Tool Identifies Slide Artifacts to Speed Digital Pathology Diagnosis
Pathology laboratories face growing case volumes, staffing pressures, and increasing diagnostic complexity that can delay results. At the same time, whole-slide images may contain quality defects such... Read more
FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Collaboration Supports Global ADC Development with AI-Powered Tissue Analysis
Selecting patients for antibody-drug conjugates (ADCs) increasingly requires broader tissue context, as target expression alone may not fully explain therapeutic response. Laboratories and translational... Read more
Standardized Staining Technology Advances Digital Pathology Workflows
Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools.... Read more
Global Testing Service Advances Leukemia MRD Monitoring
KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more






 Assay.jpg)

